General “News” category

Latest Update to Lung-RADS (1.1) is Complete!

2019-05-23T13:52:14+00:00May 23rd, 2019|Hot Topics, News|

Over the weekend, the long-awaited update of Lung-RADS was published with changes that aim to reduce lung cancer screening false positives by downgrading many category 3 findings to category 2. Lung-RADS (lung imaging reporting and data system) is a quality assurance tool to aid with findings in low-dose CT screenings for lung cancer. First introduced in 2014 by the American College of Radiology, Lung-RADS aims to standardize recommendations, reduce confusion in screening interpretations, and facilitate outcome monitoring. Here are the [...]

Patient Voices Were Heard: Preserving Access to Life Saving Drug Therapies!

2019-05-21T16:16:21+00:00May 21st, 2019|Hot Topics, News|

On May 17, 2019, The Centers for Medicare & Medicaid Services (CMS) released the final Medicare Part D Rule, where they decided to preserve the original Six Protected Classes policy. GO2 Foundation for Lung Cancer (formerly Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) advocated to stop the initial proposal that would have excluded certain drugs, including the Six Protected Classes from the Medicare Plan formularies. The Six Protected Classes policy was established over a decade ago to [...]

Research Wins Big

2019-05-17T16:57:20+00:00May 7th, 2019|Hot Topics, News|

The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care”—individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for patients. We [...]

FDA Approves First-Line Treatment for NSCLC with PD-L1 Biomarker

2019-04-12T17:39:26+00:00April 12th, 2019|Hot Topics, News|

On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.

Priority Focus Renewed on Women’s Health Imperative – House and Senate Leaders Reintroduce Women and Lung Cancer Research and Preventive Services Act of 2019

2019-04-10T19:48:13+00:00April 10th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer hails bipartisan effort to accelerate progress to increase survivorship April 10, 2019 - Today the GO2 Foundation for Lung Cancer praises Senators Marco Rubio (R-FL), Dianne Feinstein (D-CA), Shelley Moore Capito (R-WV), and Joe Manchin (D-WV), and Representatives Brendan Boyle (D-PA), Brian Fitzpatrick (R-PA), Debbie Dingell (D-MI), and Suzanne Bonamici (D-OR) for elevating national attention to a women’s public health imperative by re-introducing the 2018 Senate and House bills (S. 2358 and H.R. 4897) as the Women [...]

Transforming Cancer Care

2019-04-03T20:21:17+00:00April 3rd, 2019|Hot Topics, News|

The landscape of cancer care is changing at a rapid pace with more research and treatment options than ever before. As exciting as these advancements are, the community standing by each cancer patient is equally important. Medical professionals, families, friends, advocates and organizations offering support services all play a crucial role in a survivor’s cancer journey. Our President and CEO, Laurie Fenton Ambrose, shared her perspective with The Washington Post on why community and partnerships are key to better cancer care. [...]

New First-Line Treatment Approved for Small Cell Lung Cancer

2019-03-19T20:57:12+00:00March 19th, 2019|Hot Topics, News|

On March 18, the U.S. Food and Drug Administration approved a combination of the immunotherapy atezolizumab (Tecentriq) along with standard chemotherapy (carboplatin and etoposide) for patients who are starting treatment for extensive stage small cell lung cancer. This is the first immunotherapy approved up front, as a first treatment, for small cell lung cancer (SCLC). The approval was based on the IMPower133 clinical trial which showed that more patients survived longer when taking the combination than standard chemotherapy. Click here [...]

LCA Joins ACS CAN in Efforts to Protect Patient Access to Lifesaving Treatment

2019-01-17T20:05:01+00:00January 17th, 2019|Hot Topics, News|

Thursday, January 17 – Lung Cancer Alliance joins a long list of leading patient advocacy groups in support of American Cancer Society Cancer Action Network’s (ASC CAN) advertising campaign, urging the U.S. Administration and Congress not to limit patient access to lifesaving medications covered under Medicare, and to ensure the Six Protected Classes policy is preserved. The Six Protected Classes policy offers patients access to cutting-edge FDA-approved therapies for epilepsy, mental illness, cancer, HIV-Aids and organ transplants. A proposal from [...]

Get Well Soon Justice Ginsburg

2018-12-21T21:38:16+00:00December 21st, 2018|Hot Topics, News|

On behalf of the lung cancer community we serve, we send our best wishes for a speedy recovery to Supreme Court Justice Ruth Bader Ginsburg. According to a Supreme Court press release, Justice Ginsburg is now resting comfortably after undergoing a pulmonary lobectomy today. Two nodules, found to be malignant on initial pathology evaluation, were removed. The nodules were incidental findings from tests used to diagnose and treat Justice Ginsburg’s recent rib fractures from a November 7 fall. “We are relieved [...]

A Message from LCA’s President

2018-12-19T16:31:37+00:00December 19th, 2018|Hot Topics, News|

To the Lung Cancer Community, As 2018 prepares to come to a close, let’s take this moment to reflect upon what we have accomplished to improve survivorship, provide support and bring our community together in a lasting and meaningful way. Together we secured millions more dollars in federal research funding, helped hundreds of patients navigate clinical trials and get molecular testing, launched a screening campaign to help people talk with their physicians about lung cancer screening and their risk, enhanced [...]